Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
The condition has an estimated prevalence of 25,000 patients in the US and an annual incidence of one to three new cases per 100,000 people. CK0804 is an
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).